As PP2A inhibition contributes to the hyperphosphorylation of tau, PP2A dysfunction can contribute to the pathogenesis and severity of several tauopathies, including Alzheimer’s Disease (AD), progressive supranuclear palsy (PSP), and Parkinsonism–dementia complex (PDC) [4,6,69,70]. This evidence concerns the gene MAPT and tauopathy.